826 related articles for article (PubMed ID: 27806687)
1. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
2. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
[TBL] [Abstract][Full Text] [Related]
3. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Iversen A; Kalin M; Giske CG
Microb Drug Resist; 2012 Apr; 18(2):189-92. PubMed ID: 22204597
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
6. Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Syre H; Hetland MAK; Bernhoff E; Bollestad M; Grude N; Simonsen GS; Löhr IH
APMIS; 2020 Mar; 128(3):232-241. PubMed ID: 31755584
[TBL] [Abstract][Full Text] [Related]
7. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
Cohen Stuart J; Leverstein-Van Hall M; Kortmann W; Verlind J; Mulder F; Scharringa J; Fluit A; Ekkelenkamp M
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
[TBL] [Abstract][Full Text] [Related]
8. Results from a Prospective
Fuchs F; Hamprecht A
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917983
[TBL] [Abstract][Full Text] [Related]
9. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
[TBL] [Abstract][Full Text] [Related]
10. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
[TBL] [Abstract][Full Text] [Related]
11. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
12. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
[TBL] [Abstract][Full Text] [Related]
13. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
Auer S; Wojna A; Hell M
Antimicrob Agents Chemother; 2010 Sep; 54(9):4006-8. PubMed ID: 20585127
[TBL] [Abstract][Full Text] [Related]
14. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.
Espinar MJ; Miranda IM; Costa-de-Oliveira S; Rocha R; Rodrigues AG; Pina-Vaz C
PLoS One; 2015; 10(8):e0134737. PubMed ID: 26237422
[TBL] [Abstract][Full Text] [Related]
15. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Søraas A; Sundsfjord A; Jørgensen SB; Liestøl K; Jenum PA
PLoS One; 2014; 9(1):e85889. PubMed ID: 24454943
[TBL] [Abstract][Full Text] [Related]
16. Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient.
Nielsen KL; Hansen KH; Nielsen JB; Knudsen JD; Schønning K; Frimodt-Møller N; Hertz FB; Jansåker F
Microbiologyopen; 2019 Dec; 8(12):e941. PubMed ID: 31573735
[TBL] [Abstract][Full Text] [Related]
17. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years.
Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S
World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of temocillin against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urinary tract infections in France.
Duployez C; Loïez C; Cattoen C; Wallet F; Vachée A
Med Mal Infect; 2019 Feb; 49(1):47-53. PubMed ID: 30396720
[TBL] [Abstract][Full Text] [Related]
19. Cefoxitin-based antibiotic therapy for extended-spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study.
Demonchy E; Courjon J; Ughetto E; Durand M; Risso K; Garraffo R; Roger PM
Int J Antimicrob Agents; 2018 Jun; 51(6):836-841. PubMed ID: 29378342
[TBL] [Abstract][Full Text] [Related]
20. A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.
Birgy A; Delecourt M; Geslain G; Desselas E; Caseris M; Magnan M; Mariani-Kurkdjian P; Bidet P; Bonacorsi S
J Antimicrob Chemother; 2017 Jul; 72(7):1911-1914. PubMed ID: 28369441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
